

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	8	FEB 10	COMPENDEX reloaded and enhanced
NEWS	9	FEB 11	WTEXTILES reloaded and enhanced
NEWS	10	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	19	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	20	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS	21	MAR 23	CA/CAPLUS enhanced with more than 250,000 patent equivalents from China
NEWS	22	MAR 30	IMSPATENTS reloaded and enhanced
NEWS	23	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	24	APR 07	STN is raising the limits on saved answers
NEWS EXPRESS	JUNE 27 08		CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:43:56 ON 13 APR 2009

=> File .Gerry2MBCE		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'MEDLINE' ENTERED AT 15:44:19 ON 13 APR 2009

FILE 'BIOSIS' ENTERED AT 15:44:19 ON 13 APR 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 15:44:19 ON 13 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:44:19 ON 13 APR 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

=> S (therapeutical? amount) (S) G-CSF (S) mg AND pd<=20031104
2 FILES SEARCHED...
L1 0 (THERAPEUTICAL? AMOUNT) (S) G-CSF (S) MG AND PD<=20031104

=> S (therapeutical? amount) (S) G-CSF AND pd<=20031104
2 FILES SEARCHED...
L2 0 (THERAPEUTICAL? AMOUNT) (S) G-CSF AND PD<=20031104

=> S (therapeutical? (3A) amount) (S) G-CSF AND pd<=20031104
2 FILES SEARCHED...
L3 5 (THERAPEUTICAL? (3A) AMOUNT) (S) G-CSF AND PD<=20031104

=> Dup rem L3
PROCESSING COMPLETED FOR L3
L4 3 DUP REM L3 (2 DUPLICATES REMOVED)
 ANSWER '1' FROM FILE MEDLINE
 ANSWERS '2-3' FROM FILE CAPLUS

=> D Ibib abs L4 1-3

L4	ANSWER 1 OF 3	MEDLINE on STN	DUPLICATE 1
ACCESSION NUMBER:	1999426533	MEDLINE	
DOCUMENT NUMBER:	10498245	PubMed ID:	
TITLE:	Persistent, therapeutically relevant levels of human granulocyte colony-stimulating factor in mice after systemic delivery of adeno-associated virus vectors.		
AUTHOR:	Koeberl D D; Bonham L; Halbert C L; Allen J M; Birkebæk T; Miller A D		

CORPORATE SOURCE: Fred Hutchinson Cancer Research Center, Seattle, WA
98109-1024, USA.

CONTRACT NUMBER: DK47754 (United States NIDDK NIH HHS)
HL3644 (United States NHLBI NIH HHS)

SOURCE: Human gene therapy, (1999 Sep 1) Vol. 10, No. 13,
pp. 2133-40.

Journal code: 9008950. ISSN: 1043-0342.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199910

ENTRY DATE: Entered STN: 11 Jan 2000

Last Updated on STN: 11 Jan 2000

Entered Medline: 27 Oct 1999

AB Adeno-associated virus (AAV) vectors have been shown to preferentially transduce hepatocytes after systemic administration in adult mice and to provide long-term expression of introduced genes. One application of this technology would be for the production of granulocyte colony-stimulating factor (G-CSF), which increases mature neutrophil numbers in humans and in animals, and has therapeutic effects in disorders featuring chronic neutropenia, including cyclic, severe congenital, and idiopathic neutropenia, and glycogen storage disease type Ib. We have treated mice by tail vein injection of AAV vectors encoding human G-CSF, and have detected high G-CSF levels and marked elevation of neutrophil counts for at least 5 months. A therapeutically relevant amount of G-CSF production was obtained when the liver-specific mouse albumin promoter-enhancer was used to drive G-CSF expression. In mice receiving higher amounts of vector, plasma levels of human G-CSF gradually increased over 3 weeks to high concentrations, whereas for lower amounts human G-CSF remained at initial, low levels. The previously observed effect of gamma irradiation, to increase AAV transduction rates, was diminished when large amounts of vector were used. Absolute neutrophil counts increased 10- to 50-fold for the period of observation to levels that would be therapeutic in the treatment of cyclic neutropenia. In conclusion, gene therapy with AAV vectors synthesizing G-CSF shows promise for the treatment of disorders featuring neutropenia.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:394304 CAPLUS

DOCUMENT NUMBER: 127:4088

ORIGINAL REFERENCE NO.: 127:951a,954a

TITLE: Novel uses of mammalian CTLA-8 and related reagents

INVENTOR(S): Banchemau, Jacques; Djossou, Odille; Flores-Romo, Leopoldo; Fossiez, Francois; Golstein, Pierre; Krishna, Mala; Lebecque, Serge J. E.; Murray, Richard

PATENT ASSIGNEE(S): Schering Corporation, USA; Institut National De La Sante Et De La Recherche Medicale

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9715320	A1	19970501	WO 1996-US16315	19961023 <--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL,				

IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO,
 NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN
 RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
 MR, NE, SN, TD, TG

CA 2235951 A1 19970501 CA 1996-2235951 19961023 <--
 CA 2235951 C 20030401
 AU 9674399 A 19970515 AU 1996-74399 19961023 <--
 EP 862454 A1 19980909 EP 1996-936385 19961023 <--
 EP 862454 B1 20020828
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
 LT, LV, FI, RO
 JP 10512293 T 19981124 JP 1997-516631 19961023 <--
 JP 3253633 B2 20020204
 JP 2002145799 A 20020522 JP 2001-275810 19961023 <--
 AT 222768 T 20020915 AT 1996-936385 19961023 <--
 PT 862454 T 20021129 PT 1996-936385 19961023 <--
 ES 2181915 T3 20030301 ES 1996-936385 19961023 <--
 US 6063372 A 20000516 US 1996-736299 19961024 <--
 HK 1015692 A1 20021129 HK 1999-100811 19990227 <--

PRIORITY APPLN. INFO.:

US 1995-5909P P 19951027
 US 1995-569742 A 19951208
 JP 1997-516631 A3 19961023
 WO 1996-US16315 W 19961023

AB Comps. and method for using CTLA-8 to treat an abnormal physiolo-
 condition in an individual, e.g. microbial infection, sepsis and septic
 shock, or abnormal hematopoiesis. The methods comprise administering a
 therapeutically effective amount of CTLA-8 alone, or in
 combination with other therapeutic reagents; or a CTLA-8 antagonists (e.g.
 interleukin 6 or G-CSF).

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:620119 CAPLUS
 DOCUMENT NUMBER: 117:220119
 ORIGINAL REFERENCE NO.: 117:37879a,37882a
 TITLE: Pulmonary administration of granulocyte colony
 stimulating factor
 INVENTOR(S): Platz, Robert M.; Winters, Mark A.; Pitt, Colin G.
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: Eur. Pat. Appl., 15 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 505123	A1	19920923	EP 1992-302239	19920316 <--
EP 505123	B1	19970108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
WO 9216192	A1	19921001	WO 1992-US2126	19920313 <--
W: AU, CA, FI, JP, KR, NO				
AU 9217476	A	19921021	AU 1992-17476	19920313 <--
AU 643141	B2	19931104		
JP 05507944	T	19931111	JP 1992-509349	19920313 <--
JP 3507486	B2	20040315		
CA 2082951	C	19991221	CA 1992-2082951	19920313 <--
CN 1066192	A	19921118	CN 1992-102497	19920314 <--
IL 101235	A	19981030	IL 1992-101235	19920315 <--

ZA 9201915	A	19930428	ZA 1992-1915	19920316 <--
AT 147270	T	19970115	AT 1992-302239	19920316 <--
ES 2097866	T3	19970416	ES 1992-302239	19920316 <--
FI 106433	B1	20010215	FI 1992-5163	19921113 <--
NO 9204413	A	19930114	NO 1992-4413	19921116 <--
NO 303716	B1	19980824		

PRIORITY APPLN. INFO.:

US 1991-669792	A	19910315
WO 1992-US2126	A	19920313

AB Granulocyte-colony stimulating factor (G-CSF) can be delivered systemically in therapeutically or prophylactically effective amts. by pulmonary administration using a variety of pulmonary delivery devices, including nebulizers, metered dose inhalers and powder inhalers. Aerosol administration results in significant elevation of the neutrophil level that compares favorably with delivery by s.c. injection. G-CSF can be administered in this manner to medically treat neutropenia, or combat or prevent infections. An aerosol contained rh-G-CSF 5 mg/mL. The inhalation exposure to the aerosol in hamsters produced a neutrophil response of 9910 as compared to 10935 $\mu\text{g}/\mu\text{L}$ for 50 $\mu\text{g}/\text{kg}$ s.c. injection.

=> Log Off H

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 15:49:25 ON 13 APR 2009